Literature DB >> 11600200

Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120.

S A Jeffs1, M K Gorny, C Williams, K Revesz, B Volsky, S Burda, X H Wang, J Bandres, S Zolla-Pazner, H Holmes.   

Abstract

Recombinant gp120 of the HIV-1(IIIB) isolate (BH10 clone) has been mutated to form the PR12 protein with the first 74 C-terminal amino acids and the V1, V2 and V3 hypervariable loops deleted. A variety of studies have shown that the CD4 binding domain (CD4bd) is very well exposed in PR12 in contrast to rgp120(LAI). Using PR12 for selection of human monoclonal antibodies (MAbs) from HIV-infected individuals, five MAbs were generated with specificities to the epitopes overlapping the CD4bd (1570A,1570C,1570D,1595 and 1599). The three MAbs, 1570A, C and D, generated from one HIV-infected individual, represent one MAb as determined by sequence analysis of the V(H)3 region. Since the epitopes overlapping the CD4bd exhibit variability among HIV-1 clades, the specificity of anti-CD4bd MAbs were distinguished by differing patterns of binding to recombinant envelope proteins derived from clade A, B, C, D and E viruses. The PR12-selected MAbs were also compared with a panel of gp120-selected anti-CD4bd MAbs and showed a different range of specificities. MAb 1599 is clade B specific, MAb 1595 reacts with the A, B and D clades, while MAb 1570 recognises the most conserved epitope, as it binds to all proteins. The results show that the exposure of different epitopes in the CD4bd of the PR12 protein allows this protein to serve as an immunogen and to induce anti-CD4bd antibodies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11600200     DOI: 10.1016/s0165-2478(01)00289-9

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  15 in total

1.  In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120.

Authors:  Maria Luisa Visciano; Michael Tuen; Miroslaw K Gorny; Catarina E Hioe
Journal:  Virology       Date:  2007-12-04       Impact factor: 3.616

2.  Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Allan deCamp; Peter Hraber; Robert T Bailer; Michael S Seaman; Christina Ochsenbauer; John Kappes; Raphael Gottardo; Paul Edlefsen; Steve Self; Haili Tang; Kelli Greene; Hongmei Gao; Xiaoju Daniell; Marcella Sarzotti-Kelsoe; Miroslaw K Gorny; Susan Zolla-Pazner; Celia C LaBranche; John R Mascola; Bette T Korber; David C Montefiori
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

3.  Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.

Authors:  Rebecca L R Powell; Maxim Totrov; Vincenza Itri; Xiaomei Liu; Alisa Fox; Susan Zolla-Pazner
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

4.  Antibody-DEPENDENT, FcγRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis.

Authors:  Lautaro G Perez; Susan Zolla-Pazner; David C Montefiori
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

5.  Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120.

Authors:  Brett Spurrier; Jared M Sampson; Maxim Totrov; Huiguang Li; Timothy O'Neal; Constance Williams; James Robinson; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  Structure       Date:  2011-05-11       Impact factor: 5.006

6.  Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.

Authors:  Miroslaw K Gorny; Leonidas Stamatatos; Barbara Volsky; Kathy Revesz; Constance Williams; Xiao-Hong Wang; Sandra Cohen; Robert Staudinger; Susan Zolla-Pazner
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.

Authors:  Liuzhe Li; Xiao-Hong Wang; Constance Williams; Barbara Volsky; Olivia Steczko; Michael S Seaman; Kalpana Luthra; Phillipe Nyambi; Arthur Nadas; Véronique Giudicelli; Marie-Paule Lefranc; Susan Zolla-Pazner; Miroslaw K Gorny
Journal:  Mol Immunol       Date:  2015-05-18       Impact factor: 4.407

8.  Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop.

Authors:  David Almond; Tetsuya Kimura; XiangPeng Kong; James Swetnam; Susan Zolla-Pazner; Timothy Cardozo
Journal:  AIDS Res Hum Retroviruses       Date:  2010-06       Impact factor: 2.205

9.  Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens.

Authors:  S Moses Dennison; Kara Anasti; Richard M Scearce; Laura Sutherland; Robert Parks; Shi-Mao Xia; Hua-Xin Liao; Miroslaw K Gorny; Susan Zolla-Pazner; Barton F Haynes; S Munir Alam
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

10.  Human monoclonal antibody 2909 binds to pseudovirions expressing trimers but not monomeric HIV-1 envelope proteins.

Authors:  Tetsuya Kimura; Xiao-Hong Wang; Constance Williams; Susan Zolla-Pazner; Miroslaw K Gorny
Journal:  Hum Antibodies       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.